This company listing is no longer active
H1ZN34 Stock Overview
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Horizon Therapeutics Public Limited Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$58.24 |
| 52 Week High | US$61.74 |
| 52 Week Low | US$29.85 |
| Beta | 1.14 |
| 1 Month Change | 1.91% |
| 3 Month Change | -2.53% |
| 1 Year Change | 8.98% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 30.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| H1ZN34 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | 0.9% | 1.5% | 0.7% |
| 1Y | 9.0% | -4.8% | 14.9% |
Return vs Industry: H1ZN34 exceeded the BR Biotechs industry which returned -6.7% over the past year.
Return vs Market: H1ZN34 exceeded the BR Market which returned -19.7% over the past year.
Price Volatility
| H1ZN34 volatility | |
|---|---|
| H1ZN34 Average Weekly Movement | 3.3% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in BR Market | 8.7% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: H1ZN34 has not had significant price volatility in the past 3 months.
Volatility Over Time: H1ZN34's weekly volatility has decreased from 8% to 3% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 2,115 | Tim Walbert | www.horizontherapeutics.com |
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use.
Horizon Therapeutics Public Limited Company Fundamentals Summary
| H1ZN34 fundamental statistics | |
|---|---|
| Market cap | R$131.44b |
| Earnings (TTM) | R$2.75b |
| Revenue (TTM) | R$19.15b |
47.8x
P/E Ratio6.9x
P/S RatioIs H1ZN34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| H1ZN34 income statement (TTM) | |
|---|---|
| Revenue | US$3.63b |
| Cost of Revenue | US$828.49m |
| Gross Profit | US$2.80b |
| Other Expenses | US$2.28b |
| Earnings | US$521.48m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.28 |
| Gross Margin | 77.17% |
| Net Profit Margin | 14.37% |
| Debt/Equity Ratio | 50.5% |
How did H1ZN34 perform over the long term?
See historical performance and comparison